Massimo Grandi joins Zambon as Chief Core Therapies Officer
In his new role, Grandi will be responsible for further developing Zambon's core products, expanding into new markets, new channels, and new opportunities.
Zambon, a multinational chemical-pharmaceutical company founded on the history and values of a family business committed to improving patients' lives and health, announces the appointment of Massimo Grandi as Chief Core Therapies Officer. His objective will be to further strengthen the positioning of Zambon's core products, as well as opening up new markets, new channels, and new opportunities.
Grandi's arrival confirms Zambon's strategic direction, which stands in continuity with its history and the aim of shaping the future through innovation in patient care and is strengthening its two strategic business units: the Core Therapies division, led by Massimo Grandi, and the Innovative Therapies division, which will be headed by Mirko Merletti as Chief Innovative Therapies Officer. Merletti is an experienced international pharmaceutical industry executive who previously served as Zambon's Chief Commercial Officer.
“We are focused on growing our assets and launching new projects, strengthening our operational model and expanding our presence in the many markets where Zambon operates,” said Giovanni Magnaghi, CEO of Zambon. "We are convinced that Core Therapies have significant growth potential, and that Innovative Therapies will enhance our portfolio, enabling us to continue growing with our usual determination. To achieve this, we need cross-functional expertise and experience like the one brought by Massimo Grandi. We will continue to invest in our products to fully unlock their potential, staying true to our commitment to Innovate cure & care to make patients’ lives better."
“I am very happy to have joined a company with such a long history and a unique industrial heritage. Zambon has strong brand equity and a solid, well-established product portfolio across global markets, reflecting a company with deep-rooted values and a clear vision for the future,” commented Massimo Grandi.
Grandi joins Zambon from Recordati. He holds a degree in Pharmaceutical Chemistry and Technology from the University of Pisa and earned an Executive MBA from SDA Bocconi in Milan. Along his career, he has contributed to the strong growth of pharmaceutical companies both in Italy and internationally, leading the launch of market-leading brands in the OTC and Specialty segments. In addition to Recordati, his international experience includes roles at Servier, Angelini, and Daiichi Sankyo.